Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab effectiveness after switching from fumarates or fingolimod in relapsing multiple sclerosis
2019-001341-40Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ofatumumab in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Annual relapse rate. Started Feb 2020; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-001341-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001341-40.